Pharmacophore modelling of stereoselective binding to the human organic cation transporter (hOCT1)

British Journal of Pharmacology

Volumn 151, Issue 8, 2007, Pages 1305-1314

  Moaddel, R ^a   Ravichandran, S ^b   Bighi, F ^a   Yamaguchi, R ^a,c   Wainer, I W ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SHIONOGI AND CO LTD   (Japan)

Author keywords

Affinity chromatography; Chiral recognition mechanism; Organic cation transporter; Pharmacophore model; Stereoselective binding

Indexed keywords

ATENOLOL; CHLORPROMAZINE; DISOPYRAMIDE; DOPAMINE; FENOTEROL; ISOPRENALINE; ORGANIC CATION TRANSPORTER; PROCAINAMIDE; PROPRANOLOL; PSEUDOEPHEDRINE; QUININE; THIAMINE; VERAPAMIL;

ANIMAL CELL; ARTICLE; BINDING SITE; CONTROLLED STUDY; DIASTEREOISOMER; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG PROTEIN BINDING; ENANTIOMER; ENANTIOSELECTIVITY; HYDROGEN BOND; HYDROPHOBICITY; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INTERACTION; PROTEIN STRUCTURE; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

BINDING SITES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; ORGANIC CATION TRANSPORTER 1; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34547921968     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707341     Document Type: Article

References (26)

1. Bednarczyk D, Ekins S, Wikel JH, Wright SH (2003). Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol 63: 489-498.
2. Booth TD, Wainer IW (1996). Investigation of the enantioselective separations of α-arylcarboxylic acids on an amylose tris(3,5- dimethylphenylcarbamate) chiral stationary phase using quantitative structure-enantioselective retention relationships: Identification of a conformationally driven chiral recognition mechanism. J Chromatogr A 737: 157-169.
3. Bourdet DL, Pritchard JB, Thakker DR (2005). Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther 315: 1288-1297.
4. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M (1983). CHARMm: a program for macromolecular energy, minimization, and dynamics calculations. J Comp Chem 4: 187-217.
5. Cahn RS, Ingold CK, Prelog V (1966). Specification of molecular chirality. Angew Chem Int Ed Engl 5: 385-414.
6. 50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
7. Dresser MJ, Leabman MK, Giacomini KM (2001). Transporters involved in the Elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J Pharm Sci 90: 397-420.
8. Jozwiak J, Ravichandran R, Collins JR, Wainer IW (2004). The interaction of non-competitive inhibitors alpha3 beta4 nicotinic acetylcholine receptor investigated by affinity chromatography, QSAR and molecular docking. J Med Chem 47: 4008-4021.
9. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T et al. (2005). Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 20: 379-386.
10. Koepsell H, Gorboulev V, Arndt P (1999). Molecular pharmacology of organic cation transporters in the kidney. J Membrane Biol 167: 103-117.
11. Koepsell H, Schmitt BM, Gorboulev V (2003). Organic cation transporters. Rev Physiol Biochem Pharmacol 150: 36-90.
12. Kurogi Y, Güner OF (2001). Pharmacophore modeling and three dimensional database searching for drug design using Catalyst. Current Med Chem 8: 1035-1055.
13. Li H, Sutter J, Hoffmann R (2000). HypoGen: an automated system of generating 3D predictive pharmacophore models. In: Guner OF (ed). Pharmacophore Perception, Development and Use in Drug Design, Iul Biotechnology Series 2. International University Line: La Jolla, CA, pp 171-189.
14. Moaddel R, Hamid R, Patel S, Bullock P, Wainer IW (2006). Identification of P-glycoprotein substrates using open tubular chromatography on an immobilized P-glycoprotein column: comparison of chromatographic results with Caco-2 permeability. Anal Chem Acta 578: 25-30.
15. Moaddel R, Patel S, Jozwiak K, Yamaguchi R, Ho PC, Wainer IW (2005a). Enantioselective binding to the human organic cation transporter-1 (hOCT1) determined using an immobilized hOCT1 liquid chromatographic stationary phase. Chirality 17: 501-506.
16. Moaddel R, Yamaguchi R, Ho PC, Patel S, Hsu CP, Subrahmanyam V et al. (2005b). Development and characterization of an immobilized human organic cation transporter based liquid chromatographic stationary phase. J Chromatogr B 818: 263-268.
17. Popp C, Gorboulev V, Muller TD, Gorbunov D, Shatskaya N, Koepsell H (2005). Amino acids critical for substrate affinity of rat organic cation transporter 1 line the substrate binding region in a model derived for the tertiary structure of lactose permease. Mol Pharmacol 67: 1600-1611.
18. Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D, et al., Pharmacognetics of Membrane Transporters Investigators (2003). Evolutionary conversation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA 100: 5902-5907.
19. Smellie A, Kahn SD, Teig S (1995a). An analysis of conformational coverage 1. Validation and estimation of coverage. J Chem Inf Comput Sci 35: 285-294.
20. Smellie A, Kahn SD, Teig S (1995b). 'An analysis of conformational coverage 2. Applications of conformational models'. J Chem Inf Comput Sci 35: 295-304.
21. Smellie A, Teig SL, Towbin P (1995c). Poling: promoting conformational coverage. J Comp Chem 16: 171-187.
22. Sutter J, Güner O, Hoffmann R, Li H, Waldman M (2000). Effect of variable weights and tolerances on predictive model generation. In: Guner OF (ed). Pharmacophore Perception, Development and Use in Drug Design, Iul Biotechnology Series 2. International University Line: La Jolla, CA, pp 499-511.
23. Volk C, Gorboulev V, Budiman T, Nagel G, Koepsell H (2003). Different affinities of inhibitors to the outwardly and inwardly directed substrate binding site of organic cation transporter 2. Mol Pharmacol 64: 1037-1047.
24. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM (1997). Cloning and functional expression of human organic cation transporter. Mol Pharmacol 51: 913-921.
25. Zhang L, Gorset W, Dresser MJ, Giacomini KM (1999). The interaction of n-tetraalkylammonium compounds with a human organic cation transporter, hOCT1. J Pharmacol Exp Ther 288: 1192-1198.
26. 1. J Pharmacol Exp Ther 286: 354-361.